Miltefosine Inhibits Candida Albicans and Non-albicans Candida Spp. Biofilms and Impairs the Dispersion of Infectious Cells
Overview
Pharmacology
Affiliations
Candida spp. can adhere to and form biofilms over different surfaces, becoming less susceptible to antifungal treatment. Resistance of biofilms to antifungal agents is multifactorial and the extracellular matrix (ECM) appears to play an important role. Among the few available antifungals for treatment of candidaemia, only the lipid formulations of amphotericin B (AmB) and the echinocandins are effective against biofilms. Our group has previously demonstrated that miltefosine has an important effect against Candida albicans biofilms. Thus, the aim of this work was to expand the analyses of the in vitro antibiofilm activity of miltefosine to non-albicans Candida spp. Miltefosine had significant antifungal activity against planktonic cells and the development of biofilms of C. albicans, Candida parapsilosis, Candida tropicalis and Candida glabrata. The activity profile in biofilms was superior to fluconazole and was similar to that of AmB and caspofungin. Biofilm-derived cells with their ECM extracted became as susceptible to miltefosine as planktonic cells, confirming the importance of the ECM in the biofilm resistant behaviour. Miltefosine also inhibited biofilm dispersion of cells at the same concentration needed to inhibit planktonic cell growth. The data obtained in this work reinforce the potent inhibitory activity of miltefosine on biofilms of the four most pathogenic Candida spp. and encourage further studies for the utilisation of this drug and/or structural analogues on biofilm-related infections.
Milteforan, a promising veterinary commercial product against feline sporotrichosis.
Garcia Carnero L, Pinzan C, Diehl C, de Castro P, Pontes L, Rodrigues A Microbiol Spectr. 2024; 12(10):e0047424.
PMID: 39194287 PMC: 11448087. DOI: 10.1128/spectrum.00474-24.
Milteforan, a promising veterinary commercial product against feline sporotrichosis.
Garcia Carnero L, Dos Reis T, Diehl C, de Castro P, Pontes L, Pinzan C bioRxiv. 2024; .
PMID: 38405873 PMC: 10888911. DOI: 10.1101/2024.02.14.580352.
Miltefosine: A Repurposing Drug against Mucorales Pathogens.
Xisto M, Rollin-Pinheiro R, Rochetti V, Castro-Almeida Y, Borba-Santos L, Santos-Freitas G J Fungi (Basel). 2023; 9(12).
PMID: 38132767 PMC: 10744482. DOI: 10.3390/jof9121166.
Candida parapsilosis complex in the clinical setting.
Govrins M, Lass-Florl C Nat Rev Microbiol. 2023; 22(1):46-59.
PMID: 37674021 DOI: 10.1038/s41579-023-00961-8.
Potential Inhibitory Effect of Miltefosine against Terbinafine-Resistant .
Haghani I, Akhtari J, Yahyazadeh Z, Espahbodi A, Kermani F, Javidnia J Pathogens. 2023; 12(4).
PMID: 37111492 PMC: 10146699. DOI: 10.3390/pathogens12040606.